Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PolyPid Ltd. (PYPD)
USD5.21
-0.14 (-2.62%)
IL NASDAQ Healthcare Biotechnology
Address
18 Hasivim Street 4959376
Petah Tikva, IL
Petah Tikva, IL
CEO
Dikla Czaczkes Akselbrad
Website
polypid.com
IPO
2020-06-26
CIK 1611842 ISIN IL0011326795
Description
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.21
-0.14 (-2.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
115.7K
Beta
1.43
Float Shares
6.66M
Free Float %
65.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.83% | +2.76% | -5.91% | +1.13% | +22.53% | +2.76% | +58.72% | -57.52% | -98.37% | -99.22% | -99.22% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
5.21
Low
9.00
+72.7%
Consensus
9.50
+82.3%
Median
9.50
+82.3%
High
10.00
+91.9%
DCF (Unlevered)
0.12
-97.6%
DCF (Levered)
0.22
-95.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
9.00
+72.7%
|
| All Time | 2 |
9.50
+82.3%
|
Quality scores
Altman Z-Score
-25.33
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+57.4% ★ Q1'26: +50.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-4,004.7% Q1'26: -155,200.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+176.6% Q1'26: +86.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.08× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 3 EPS Ana. |
Dec 2027 1 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 3.10M (-100.0%)
|
850.0K
673.0K – 1.03M
-72.6% YoY
|
13.08M
10.35M – 15.80M
+1,438.2% YoY
|
81.20M
64.29M – 98.11M
+521.0% YoY
|
161.50M
127.88M – 195.12M
+98.9% YoY
|
258.20M
204.44M – 311.96M
+59.9% YoY
|
| EBITDA |
-26.41M
|
-31.86M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-28.03M
|
-33.48M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-29.02M
est: -34.53M (+15.9%)
|
-34.17M
est: -33.63M (-1.6%)
|
-23.26M
-26.29M – -20.23M
+30.8% YoY
|
-20.50M
-26.05M – -14.95M
+11.8% YoY
|
1.64M
1.19M – 2.08M
+108.0% YoY
|
28.45M
20.75M – 36.15M
+1,640.0% YoY
|
61.65M
44.96M – 78.33M
+116.7% YoY
|
| SGA |
5.22M
|
9.16M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-4.91
est: -4.58 (-7.1%)
|
-2.09
est: -2.09 (+0.1%)
|
-1.43
-1.61 – -1.24
+31.8% YoY
|
-1.25
-1.59 – -0.91
+12.1% YoY
|
0.10
0.07 – 0.13
+108.0% YoY
|
1.74
1.27 – 2.21
+1,640.0% YoY
|
3.77
2.75 – 4.79
+116.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
6
Total invested
7.09M
Insider transactions (90d)
0
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Geneva Holding Company (GHC) SA | 4.22M | 8.60% | — | 4.22M | — | 4.22M | HC | United Kingdom | 2023-09-20 | ↗ |
| 2 | Geneva Trust Company (GTC) SA | 4.22M | 8.60% | — | 4.22M | — | 4.22M | HC | United Kingdom | 2023-09-20 | ↗ |
| 3 | Rodney Hodges | 4.22M | 8.60% | — | 4.22M | — | 4.22M | IN | United Kingdom | 2023-09-20 | ↗ |
| 4 | àrl | 4.22M | 8.60% | — | 4.22M | — | 4.22M | CO | United Kingdom | 2023-09-20 | ↗ |
| 5 | Centaurus Investments Limited | 3.53M | 7.20% | — | 3.53M | — | 3.53M | HC | United Kingdom | 2023-09-20 | ↗ |
| 6 | Xenia Venture Capital Limited | 3.12M | 6.40% | — | 3.12M | — | 3.12M | HC | United Kingdom | 2023-09-20 | ↗ |
| 7 | Aurum Ventures M.K.I. Ltd. | 2.03M | 10.80% | 2.03M | — | 2.03M | — | CO | Israel | 2022-02-24 | ↗ |
| 8 | Morris Kahn | 2.03M | 10.80% | — | 2.03M | — | 2.03M | IN | Israel | 2022-02-24 | ↗ |
| 9 | Gabriel Capital Management Ltd. | 1.11M | 5.90% | — | 1.11M | — | 1.11M | IA | Israel | 2022-02-10 | ↗ |
| 10 | Yehuda Nir | 914.9K | 17.60% | 914.9K | — | 914.9K | — | IN | Israel | 2024-04-05 | ↗ |
| 11 | Aharon Lukach | 471.5K | 9.40% | 471.5K | — | 471.5K | — | IN | Israel | 2024-04-17 | ↗ |
| 12 | Gilad Aharon | 415.8K | 9.95% | — | 415.8K | — | 415.8K | IN | ONTARIO, CANADA | 2024-03-01 | ↗ |
| 13 | Rosalind Master Fund L.P. | 415.8K | 9.95% | — | 415.8K | — | 415.8K | PN | ONTARIO, CANADA | 2024-03-01 | ↗ |
| 14 | Steven Salamon | 415.8K | 9.95% | — | 415.8K | — | — | IN | ONTARIO, CANADA | 2024-03-01 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
6
-13 vs prev Q
New positions
1
Closed positions
14
Increased
2
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | AIGH CAPITAL MANAGEMENT LLC | 1.59M +250.6K (+18.7%) | 6.98M +1.2M (+19.8%) | 7.74% +1.217 pp | 0.95% -0.459 pp | USD4.07 +7.6% | 9 qtrs — |
| 2 | ROSALIND ADVISORS, INC. | 597.9K -98.6K (-14.2%) | 2.62M -404.1K (-13.4%) | 2.90% -0.479 pp | 1.05% -0.010 pp | USD3.90 +12.3% | 9 qtrs — |
| 3 | DAFNA CAPITAL MANAGEMENT LLC | 207.9K +— (+0.0%) | 910.6K +8.3K (+0.9%) | 1.01% +0.000 pp | 0.21% -0.002 pp | USD4.31 +1.6% | 9 qtrs — |
| 4 | MORGAN STANLEY | 176.9K -31.4K (-15.1%) | 774.8K -129.1K (-14.3%) | 0.86% -0.152 pp | 0.00% +0.000 pp | USD3.44 +27.3% | 11 qtrs — |
| 5 | J. GOLDMAN & CO LP | 149.5K -22.8K (-13.2%) | 654.8K -93.0K (-12.4%) | 0.73% -0.111 pp | 0.02% -0.001 pp | USD3.21 +36.4% | 6 qtrs — |
| 6 | SYMMETRY PEAK MANAGEMENT LLC | 87.2K -40.1K (-31.5%) | 381.9K -170.7K (-30.9%) | 0.42% -0.195 pp | 0.11% -0.040 pp | USD3.42 +28.1% | 4 qtrs — |
| 7 | CITADEL ADVISORS LLC | 57.8K +47.0K (+438.7%) | 253.0K +206.5K (+443.7%) | 0.28% +0.229 pp | 0.00% +0.000 pp | USD4.37 +0.2% | 5 qtrs — |
| 8 | LUMBARD & KELLNER, LLC | 38.2K +— (+0.0%) | 167.3K +1.5K (+0.9%) | 0.19% +0.000 pp | 0.06% 0.000 pp | USD3.53 +24.1% | 4 qtrs — |
| 9 | XTX TOPCO LTD | 29.5K -3.2K (-9.8%) | 129.0K -12.7K (-9.0%) | 0.14% -0.016 pp | 0.00% -0.002 pp | USD3.67 +19.3% | 3 qtrs — |
| 10 | JANE STREET GROUP, LLC | 21.6K +6.4K (+42.4%) | 94.8K +28.8K (+43.7%) | 0.11% +0.031 pp | 0.00% +0.000 pp | USD4.35 +0.7% | 2 qtrs — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 18.6K +18.6K (+100.0%) | 81.5K +81.5K (+100.0%) | 0.09% +0.090 pp | 0.00% +0.000 pp | USD4.38 +0.0% | 1 qtrs NEW |
| 12 | B. RILEY WEALTH ADVISORS, INC. | 15.1K +— (+0.0%) | 63.7K -2.0K (-3.0%) | 0.07% +0.000 pp | 0.00% +0.001 pp | USD4.34 +0.9% | 2 qtrs — |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12.9K +12.9K (+100.0%) | 56.5K +56.5K (+100.0%) | 0.06% +0.063 pp | 0.00% +0.000 pp | USD4.38 +0.0% | 1 qtrs NEW |
| 14 | BNP PARIBAS ARBITRAGE, SNC | 9.2K -103.0 (-1.1%) | 40.2K -80.0 (-0.2%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD3.42 +28.1% | 6 qtrs — |
| 15 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 7.3K +— (+0.0%) | 32.2K +293.0 (+0.9%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD4.51 -2.9% | 11 qtrs — |
| 16 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 4.0K +— (+0.0%) | 17.4K +159.0 (+0.9%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD3.53 +24.1% | 4 qtrs — |
| 17 | ADVISOR GROUP HOLDINGS, INC. | 467.00 +— (+0.0%) | 2.0K +19.0 (+0.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.51 -2.9% | 11 qtrs — |
| 18 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 3.00 +3.0 (+100.0%) | 13.00 +13.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.33 +1.2% | 1 qtrs NEW |
| 19 | SBI SECURITIES CO., LTD. | 1.00 +— (+0.0%) | 4.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 +46.0% | 6 qtrs — |
| 20 | UBS GROUP AG | — -1.5K (-100.0%) | — -6.5K (-100.0%) | 0.00% -0.007 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 21 | HIGHTOWER ADVISORS, LLC | — -10.2K (-100.0%) | — -44.5K (-100.0%) | 0.00% -0.050 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Warshavsky Ori | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 267 | D | ↗ |
| 2026-03-18 | Krinsky Itzhak | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 833 | D | ↗ |
| 2026-03-18 | Jacobovitz Yitzchak Shlomo | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Barenholz Yechezkel | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 2,760 | D | ↗ |
| 2026-03-18 | Akselbrad Dikla Czaczkes | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 934 | D | ↗ |
| 2026-03-11 | Story Brooke | Director | — | — | Stock option (right to buy) | 17,456 | 4.01 | 70.0K | 0 | D | ↗ |
| 2025-08-12 | Stein Robert Benjamin | Director | — | — | Stock option (right to buy) | 14,440 | 2.67 | 38.6K | 0 | D | ↗ |
| 2025-08-12 | Krinsky Itzhak | Director | — | — | Stock option (right to buy) | 14,440 | 2.67 | 38.6K | 0 | D | ↗ |
| 2025-08-12 | Dror-Darwish Nir | Director | — | — | Stock option (right to buy) | 14,440 | 2.67 | 38.6K | 0 | D | ↗ |
| 2025-08-12 | BenAmram Joseph | Director | — | — | Stock option (right to buy) | 14,440 | 2.67 | 38.6K | 0 | D | ↗ |
| 2025-08-12 | Barenholz Yechezkel | Director | — | — | Stock option (right to buy) | 14,440 | 2.67 | 38.6K | 0 | D | ↗ |
| 2025-06-09 | Warshavsky Ori | Officer | — | — | Employee Stock option (right to buy) | 34,000 | 4.64 | 157.8K | 0 | D | ↗ |
| 2025-06-09 | Missulawin Jonathan | Officer | — | — | Employee Stock option (right to buy) | 43,000 | 4.64 | 199.5K | 0 | D | ↗ |
| 2025-06-09 | Hazan Dalit Fellous | Officer | — | — | Employee Stock option (right to buy) | 60,000 | 4.64 | 278.4K | 0 | D | ↗ |
| 2025-06-09 | Akselbrad Dikla Czaczkes | Director / Officer | — | — | Stock option (right to buy) | 132,600 | 4.64 | 615.3K | 0 | D | ↗ |
| 2024-10-02 | Stein Robert Benjamin | Director | — | — | Stock option (right to buy) | 6,500 | 4.24 | 27.6K | 0 | D | ↗ |
| 2024-10-02 | Krinsky Itzhak | Director | — | — | Stock option (right to buy) | 6,500 | 4.24 | 27.6K | 0 | D | ↗ |
| 2024-10-02 | Dror-Darwish Nir | Director | — | — | Stock option (right to buy) | 6,500 | 4.24 | 27.6K | 0 | D | ↗ |
| 2024-10-02 | BenAmram Joseph | Director | — | — | Stock option (right to buy) | 6,500 | 4.24 | 27.6K | 0 | D | ↗ |
| 2024-10-02 | Barenholz Yechezkel | Director | — | — | Stock option (right to buy) | 6,500 | 4.24 | 27.6K | 0 | D | ↗ |
| 2024-08-07 | Warshavsky Ori | Officer | — | — | Employee Stock option (right to buy) | 7,667 | 11.01 | 84.4K | 0 | D | ↗ |
| 2024-08-07 | Missulawin Jonathan | Officer | — | — | Employee Stock option (right to buy) | 10,000 | 11.01 | 110.1K | 0 | D | ↗ |
| 2024-08-07 | Hazan Dalit Fellous | Officer | — | — | Employee Stock option (right to buy) | 14,667 | 11.01 | 161.5K | 0 | D | ↗ |
| 2024-08-07 | Akselbrad Dikla Czaczkes | Director / Officer | — | — | Stock option (right to buy) | 30,486 | 11.01 | 335.7K | 0 | D | ↗ |
| 2023-08-08 | BenAmram Joseph | Director | — | — | Stock option (right to buy) | 625 | 11.40 | 7.1K | 0 | D | ↗ |
| 2023-08-05 | Stein Robert Benjamin | Director | — | — | Stock option (right to buy) | 312 | 11.40 | 3.6K | 0 | D | ↗ |
| 2023-08-05 | Krinsky Itzhak | Director | — | — | Stock option (right to buy) | 312 | 11.40 | 3.6K | 0 | D | ↗ |
| 2023-08-05 | Dror-Darwish Nir | Director | — | — | Stock option (right to buy) | 312 | 11.40 | 3.6K | 0 | D | ↗ |
| 2023-08-05 | Barenholz Yechezkel | Director | — | — | Stock option (right to buy) | 312 | 11.40 | 3.6K | 0 | D | ↗ |
| 2023-07-01 | Akselbrad Dikla Czaczkes | Director / Officer | — | — | Stock option (right to buy) | 3,333 | 23.07 | 76.9K | 0 | D | ↗ |
| 2022-08-09 | Warshavsky Ori | Officer | — | — | Employee Stock option (right to buy) | 794 | 23.07 | 18.3K | 0 | D | ↗ |
| 2022-08-09 | Missulawin Jonathan | Officer | — | — | Employee Stock option (right to buy) | 667 | 23.07 | 15.4K | 0 | D | ↗ |
| 2022-08-09 | Hazan Dalit Fellous | Officer | — | — | Employee Stock option (right to buy) | 1,165 | 23.07 | 26.9K | 0 | D | ↗ |
| 2022-08-03 | Stein Robert Benjamin | Director | — | — | Stock option (right to buy) | 312 | 23.07 | 7.2K | 0 | D | ↗ |
| 2022-08-03 | Krinsky Itzhak | Director | — | — | Stock option (right to buy) | 312 | 23.07 | 7.2K | 0 | D | ↗ |
| 2022-08-03 | Dror-Darwish Nir | Director | — | — | Stock option (right to buy) | 312 | 23.07 | 7.2K | 0 | D | ↗ |
| 2022-08-03 | Barenholz Yechezkel | Director | — | — | Stock option (right to buy) | 312 | 23.07 | 7.2K | 0 | D | ↗ |
| 2017-08-25 | Hazan Dalit Fellous | Officer | — | — | Employee Stock option (right to buy) | 47 | 92.89 | 4.4K | 0 | D | ↗ |
| 2017-08-25 | Akselbrad Dikla Czaczkes | Director / Officer | — | — | Stock option (right to buy) | 228 | 92.89 | 21.2K | 0 | D | ↗ |
| 2017-04-01 | Missulawin Jonathan | Officer | — | — | Employee Stock option (right to buy) | 20 | 123.01 | 2.5K | 0 | D | ↗ |
| 2017-03-21 | Akselbrad Dikla Czaczkes | Director / Officer | — | — | Stock option (right to buy) | 1,713 | 117.99 | 202.1K | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
10.19M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dikla Czaczkes Akselbrad | Chief Executive Officer & Director | 558.3K | female |
| Ori Warshavsky | Chief Operating Officer - US | 418.5K | male |
| Dalit Hazan | Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs | 394.8K | female |
| Jonny Missulawin | Chief Financial Officer | 270.6K | male |
| Rivi Lev-ari | Vice President of Human Resource | — | female |
| Tal Vilnai | General Counsel & Corporate Secretary | — | male |
| Jean-Marc Hagai | Chief Commercial Officer | — | — |
| Maria Rubin | Executive Vice President of Operations | — | female |
| Nurit Tweezer-Zaks | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PYPD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
